Recently, Nguyen T. and colleagues reported the in vitro/in vivo synergic efficacy of PF-00477736 in combination with the Src/ABL inhibitor bosutinib (SKI-606) in BCR-ABL1-positive CML or ALL cells, focusing on highly imatinib-resistant models with ABL kinase mutations. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.